US Patent

US11654124 — Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives

Formulation · Assigned to Amneal Pharmaceuticals LLC · Expires 2039-07-29 · 13y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stabilized formulations of the active ingredient 4-amino-3-substituted butanoic acid derivatives, including baclofen and its salts.

USPTO Abstract

Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts.

Drugs covered by this patent

Patent Metadata

Patent number
US11654124
Jurisdiction
US
Classification
Formulation
Expires
2039-07-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Amneal Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.